Sökning: id:"swepub:oai:gup.ub.gu.se/58328" >
Early versus peripr...
Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies.
-
Gödicke, Jochen (författare)
-
Flather, Marcus (författare)
-
Noc, Marko (författare)
-
visa fler...
-
Gyöngyösi, Mariann (författare)
-
Arntz, Hans-Richard (författare)
-
- Grip, Lars, 1952 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
Gabriel, Henrique Mesquita (författare)
-
Huber, Kurt (författare)
-
Nugara, Fiona (författare)
-
Schröder, Joachim (författare)
-
- Svensson, Leif (författare)
- Karolinska Institutet
-
Wang, Duolao (författare)
-
Zorman, Simona (författare)
-
Montalescot, Gilles (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2005
- 2005
- Engelska.
-
Ingår i: American heart journal. - : Elsevier BV. - 1097-6744 .- 0002-8703. ; 150:5
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: The 2004 ACC/AHA guidelines on ST-elevation myocardial infarction state that it is reasonable to start treatment with abciximab as early as possible before primary percutaneous coronary intervention (PCI). We investigated the potential benefit of early use of abciximab by pooling data from all the available studies. METHODS: Six prospective studies were identified that had allocated 260 patients to receive early abciximab (either prehospital or soon after the patient arrived in hospital) and 342 to receive late abciximab (at the time of PCI). RESULTS: TIMI flow grade 2 or 3 was present in 42% of the early group compared with 29% in the late group (P = .001). After PCI, 59% of patients in the early group showed ST-resolution >or = 70%, compared with 41% in the late group (P = .003). The composite clinical outcomes death, new myocardial infarction, or repeat target vessel revascularization at 30 days occurred in 7.3% of the early group compared with 9.7% in the late group (odds ratio 0.73, 95% CI 0.41-1.32) and death alone occurred in 2.7% versus 4.7%, respectively (odds ratio 0.56, 95% CI 0.23-1.39). CONCLUSIONS: Early administration of abciximab improves epicardial patency (TIMI flow) before PCI and results in better myocardial tissue perfusion (ST-resolution) after the procedure. The promising effects on clinical outcomes need to be tested in larger studies.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Angioplasty
- Transluminal
- Percutaneous Coronary
- Antibodies
- Monoclonal
- administration & dosage
- Female
- Humans
- Immunoglobulin Fab Fragments
- administration & dosage
- Male
- Middle Aged
- Time Factors
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gödicke, Jochen
-
Flather, Marcus
-
Noc, Marko
-
Gyöngyösi, Maria ...
-
Arntz, Hans-Rich ...
-
Grip, Lars, 1952
-
visa fler...
-
Gabriel, Henriqu ...
-
Huber, Kurt
-
Nugara, Fiona
-
Schröder, Joachi ...
-
Svensson, Leif
-
Wang, Duolao
-
Zorman, Simona
-
Montalescot, Gil ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
American heart j ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet